Hu-PHEC is an exciting pipeline for Hemogenyx, in a nutshell each year thousands of patents require Bone Marrow Transplant for a range of different conditions. However in most cases a donor is required, this means identifying a matching candidate and harvesting BM from them before processing it ready for transplantation. This screening means that many times more people will be tested for a match for every successful transplantation, the donor will have to undergo several appointments and undergo tests and minor surgery to remove the BM. While results are often good rejection of BM can occur, there is also a risk of transferring a previously diagnosed illness or medical condition from the donor to the patent. Ultimately a match may not be found in time to save the patent.
Hu-PHECs are a special sub-class of progenitor stem cell that generate hematopoietic stem cells (HSCs): bone marrow cells that give rise to all major types of blood cells. Hu-PHECs are thought to be cancer-free as they do not accumulate blood cancer-related mutations and/or chromosomal rearrangements. They come from the Patent, a donor is NOT required, the chance of rejection or cross infection or the delay incurred with screening donors for a match all disappear.
Hemogenyx have secured US and worldwide protection for Hu-PHEC.
The Company’s subsidiary in Belgium, Hemogenyx-Cell SPRL, has been considering plans with a number of potential Belgian-based partners, including Orgenesis, Inc. regarding key building blocks for the path through development towards clinical trials of Hu-PHECs, including the establishment of a cell bank.
In 1992, the United States spent 817 billion dollars on health care (14% of gross national product), comprising the world’s most expensive health care system. Out of this expenditure, bone marrow transplantation (BMT) accounted for $810 million with procedure costs averaging between $100,000 and $300,000 per patient, making it one of the single most costly health care procedures. Per stem cell journals
In the UK A transplant costs between £50,000 and £120,000, but the cost of caring for one patient refused a transplant in those few years was £130,000 for the year they survived, and for another patient who survived three years it was £160,000.
In 2018, 4,992 unrelated and 4,275 related bone marrow and cord blood transplants were performed in the United States and reported to CIBMTR. This figure shows that the Hemogenyx are targeting a multi-billion pound market with Hu-PHEC. This is a disruptive treatment that potentially could save time, money and lives by reducing the need for BM donors in future.
Hu-PHEC is protected, the next step is Clinical Trials, but this requires the production in a lab of cells ready for transplantation. This is an expensive procedure and will require significant investment in physical facilities and this means it will take time. Its unlikely there will be any more clinical advances here until we hear news about how it will be financed, this may mean Hemogenyx raise the funds themselves, or licence the product or some sort of Joint Venture IE with Orgenesis who can provide the financial support.